Predictive Oncology Inc. (POAI)

NASDAQ: POAI · Real-Time Price · USD

0.7620

-0.0270 (-3.42%)

At close: Aug 1, 2025, 4:00 PM

0.7500

-0.0120 (-1.57%)

After-hours: Aug 1, 2025, 7:54 PM EDT

Verve Therapeutics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Verve Therapeutics.

Price Target: $0.00 (0.00%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

According to 1 stock analyst, the rating for Verve Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0
Buy	0	0	0	0
Hold	1	1	1	1
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Nov 15, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $3	Strong Buy	Initiates	$3	+293.70%	Aug 19, 2024
Vernon Bernardino HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $100	Strong Buy	Initiates	$100	+13,023.36%	Jun 30, 2021

More Analyst Ratings

Financial Forecast

Revenue This Year

9.52M

from 1.62M

486.27%

from 1.62M

Revenue Next Year

15.76M

from 9.52M

65.50%

from 9.52M

EPS This Year

-0.13

from -2.32

EPS Next Year

0.08

from -0.13

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.25M	1.42M	1.51M	1.63M	1.62M	9.52M	15.76M	24.45M
Revenue Growth	-11.29%	13.45%	5.97%	8.12%	-0.24%	486.27%	65.50%	55.17%
EPS	-44.25	-7.20	-6.98	-3.48	-2.32	-0.13	0.08	0.28
EPS Growth	-	-	-	-	-	-	-	237.50%
Forward PE	-	-	-	-	-	-	9.34	2.77
No. Analysts	-	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	9.8M	16.2M	25.2M
Avg	9.5M	15.8M	24.4M
Low	9.1M	15.1M	23.5M

Revenue Growth

Revenue Growth	2025	2026	2027
High	503.5%	70.4%	59.7%
Avg	486.3%	65.5%	55.2%
Low	463.2%	59.0%	49.1%

EPS Forecast

EPS	2025	2026	2027
High	-0.14	0.08	0.28
Avg	-0.13	0.08	0.28
Low	-0.13	0.08	0.26

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	247.4%
Avg	-	-	237.5%
Low	-	-	224.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.